☆ 4.8 Article

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma

FRONTIERS IN IMMUNOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Long-term remissions in patients with early relapse of diffuse large B-cell lymphoma following high-dose chemotherapy, autologous stem cell transplantation, and radiotherapy of residual disease

Bernd Metzner et al.

Summary: For early relapse patients of DLBCL, sustained long-term remissions can be achieved following ASCT in a second or third treatment line, especially in low- and low-intermediate-risk IPI patients, after radiotherapy of residual disease post-ASCT. Further investigations are needed to determine which patients could benefit from alternative therapies.

STRAHLENTHERAPIE UND ONKOLOGIE (2022)

Add to Collection

Article Hematology

Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma

Ying Liu et al.

Summary: Sequential CAR T-cell therapy targeting different B-cell antigens appears to be a feasible and effective approach for pediatric relapsed/refractory Burkitt lymphoma, leading to durable response rates and high progression-free survival rates.

BLOOD ADVANCES (2022)

Add to Collection

Review Pharmacology & Pharmacy

Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma

Zachery Halford et al.

Summary: The literature review suggests that axicabtagene ciloleucel has shown promising efficacy in the treatment of relapsed/refractory large B-cell lymphoma, but also comes with unique and potentially life-threatening toxicities that need to be carefully monitored. Further studies are needed to determine the ideal place of axi-cel in LBCL therapy.

ANNALS OF PHARMACOTHERAPY (2021)

Add to Collection

Article Oncology

CAR19/22 T cell therapy in adult refractory Burkitt's lymphoma

Xiaoxi Zhou et al.

Summary: The study evaluated the efficacy and safety of CAR19/22 T cell therapy in six refractory Burkitt's lymphoma cases, showing that three patients achieved an objective response and patients with bulky disease had poorer prognosis.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Immunology

Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy

Victor E. Tedesco et al.

Summary: CAR-T cell therapy has shown remarkable efficacy in treating hematological malignancies, but also comes with life-threatening toxicities like cytokine release syndrome and neurotoxicity. This research reviewed 33 clinical trials to identify biomarkers that can predict the severity of posttreatment CRS and neurotoxicity, showing promising potential in using combinatorial algorithms based on cytokine levels and clinical parameters for improved accuracy.

JOURNAL OF IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment

Zhiling Yan et al.

Summary: Clinical trials have shown that CAR T cell therapies are changing the treatment of relapsed or refractory hematological tumors, with CRS being a common adverse event. Understanding the characteristics and risk factors of CRS is crucial for effective management. Different B-cell hematological tumors have varying characteristics and risk factors for CRS during CAR-T cell therapy.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

CAR T-Cell Therapy in Hematological Malignancies

Theresa Haslauer et al.

Summary: CAR T-cells are a promising therapeutic approach for hematological malignancies, particularly in lymphoma and acute lymphocytic leukemia. Despite encouraging clinical results, challenges remain in treating other hematological malignancies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Oncology

Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma

Jiaying Wu et al.

Summary: The study treated 13 patients with CNSL using ASCT sequential CD19/22 CAR T-cell infusion. The results showed promising long-term efficacy and relatively manageable side effects of this treatment approach.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Review Pharmacology & Pharmacy

Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope

Alejandrina Hernandez-Lopez et al.

Summary: Cancer is a leading cause of death worldwide, and immunotherapy, particularly CAR-T cell therapy, has shown promise in treating patients who have not responded to traditional treatments. However, there are still challenges to overcome in making this technology a first-line clinical treatment.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy

Sylvain Lamure et al.

Summary: In this study of 60 patients with relapsed/refractory diffuse large B-cell lymphoma and transformed follicular lymphoma who received CD19-directed CAR T-cell therapy, a complete metabolic response was achieved in 40% of patients, with a partial metabolic response in 23%. Factors such as age-adjusted international prognostic index, product features, in vivo expansion, and CAR T-cell exhaustion phenotype were significantly associated with the efficacy of the therapy.

CANCERS (2021)

Add to Collection

Article Hematology

CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas

Yang Cao et al.

Summary: The study evaluated the safety and efficacy of sequential infusion of CD19/22 CAR T cells following HDT-ASCT for patients with R/R aggressive B-NHL, showing an overall response rate of 90.5% and a 2-year progression-free survival rate of 83.3%. No patients were found to be CD19- and CD22-negative, with 97.1% and 68.6% of patients with ongoing complete remission having consistently detectable levels of CAR transgene.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

Article Cell & Tissue Engineering

Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Tianyi Wang et al.

Summary: The case report demonstrates successful treatment of refractory Burkitt lymphoma-post-transplant lymphoproliferative disorder (BL-PTLD) with autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The patient achieved complete remission (CR) and 16 months event-free survival after the treatment.

CELL TRANSPLANTATION (2021)

Add to Collection

Article Hematology

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Andrew M. Evens et al.

Summary: The study found that patients with Burkitt lymphoma who received rituximab treatment had higher survival rates, while factors such as age, ECOG performance status, lactate dehydrogenase levels, and central nervous system involvement could affect patient survival.

BLOOD (2021)

Add to Collection

Article Hematology

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

Na Wang et al.

BLOOD (2020)

Add to Collection

Article Hematology

High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey

Sung-Won Kim et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)

Add to Collection

Article Hematology

Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy

Wilhelm Woessmann et al.

BLOOD (2020)

Add to Collection

Article Hematology

Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells

Wenqun Zhang et al.

BLOOD (2020)

Add to Collection

Review Oncology

Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review

Juan Du et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)

Add to Collection

Article Immunology

Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma

Tao Wang et al.

IMMUNOTHERAPY (2020)

Add to Collection

Letter Oncology

Long-term outcomes of relapsed/refractory double-hit lymphoma (r/r DHL) treated with CD19/22 CAR T-cell cocktail therapy

Jia Wei et al.

CLINICAL AND TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Hematology

The treatment of Burkitt lymphoma in adults

Jennifer Crombie et al.

BLOOD (2020)

Add to Collection

Article Hematology

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Laetitia Vercellino et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Biochemistry & Molecular Biology

The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma

Jianshu Wei et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Add to Collection

Article Hematology

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Alexandre V. Hirayama et al.

BLOOD (2019)

Add to Collection

Review Oncology

Mechanisms of resistance to CAR T cell therapy

Nirali N. Shah et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

B-Cell Lymphomas, Version 3.2019 Featured Updates to the NCCN Guidelines

Andrew D. Zelenetz et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)

Add to Collection

Article Oncology

Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study

Charlotte Rigaud et al.

PEDIATRIC BLOOD & CANCER (2019)

Add to Collection

Article Hematology

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Daniel W. Lee et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Add to Collection

Review Hematology

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

Jennifer N. Brudno et al.

BLOOD REVIEWS (2019)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Letter Biophysics

CAR T cells induce a complete response in refractory Burkitt Lymphoma

Abraham Avigdor et al.

BONE MARROW TRANSPLANTATION (2018)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Hematology

Burkitt lymphoma- a rare but challenging lymphoma

Carla Casulo et al.

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)

Add to Collection

Letter Hematology

Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma

Nicholas J. Short et al.

AMERICAN JOURNAL OF HEMATOLOGY (2017)

Add to Collection

© Peeref 2019-2024. All rights reserved.